Milatuzumab-doxorubicin conjugate

Drug Profile

Milatuzumab-doxorubicin conjugate

Alternative Names: CD-74-DOX; hCD74-DOX; hLL1-DOX; IMMU-110; Milatuzumab-DOX

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Feb 2016 No development reported - Phase-I/II for Non-Hodgkin's lymphoma (Recurrent, Second-line therapy or greater) in USA (IV)
  • 25 Feb 2016 No development reported - Phase-I/II for Multiple myeloma (Recurrent) in USA (IV)
  • 25 Feb 2016 No development reported - Phase-I/II for Chronic lymphocytic leukaemia (Recurrent, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top